Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 10/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | BCL6 | P41182 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26835287 | 1.00 | CCR4 (0.43) | CCR4NAMPTSOS1P2RX3KDM4E | |
| SCHEMBL26611445 | 1.00 | CCR4 (0.43) | CCR4NAMPTSOS1P2RX3KDM4E | |
| SCHEMBL26611439 | 1.00 | CCR4 (0.43) | CCR4NAMPTSOS1P2RX3KDM4E | |
| SCHEMBL26611443 | 1.00 | CCR4 (0.43) | CCR4NAMPTSOS1P2RX3KDM4E | |
| SCHEMBL26831714 | 1.00 | CCR4 (0.43) | CCR4NAMPTSOS1P2RX3KDM4E | |
| SCHEMBL26831678 | 0.95 | CCR4 (0.45) | CCR4SOS1P2RX3 | |
| SCHEMBL26831672 | 0.95 | CCR4 (0.45) | CCR4SOS1P2RX3 | |
| SCHEMBL26831365 | 0.94 | CCR4 (0.42) | CCR4NAMPTSOS1P2RX3KDM4E | |
| SCHEMBL26831356 | 0.94 | KDM4E (0.40) | CCR4NAMPTP2RX3KDM4ELMNA | |
| SCHEMBL30619258 | 0.93 | IDH1 (0.42) | CCR4NAMPTP2RX3KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382894-A1 | CCR4 ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382894-A1 | CCR4 ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382894-A1 | CCR4 ANTAGONISTS | CCR4, CCR1, CCR3 | CCR4 1/4885NAMPT 3631/4885SOS1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.